Pharmaceutical risk-sharing agreements

PharmacoEconomics

Volumn 26, Issue 7, 2008, Pages 551-556

  Cook, Joseph P ^a   Vernon, John A ^b   Manning, Richard ^c  

^a NERA ECONOMIC CONSULTING   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c PFIZER INC   (United States)

Author keywords

Drug utilisation; Formularies; Health policy; Pharmaceutical industry; Pharmaceutical risk management

Indexed keywords

CONSUMER; DECISION MAKING; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MEDICARE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK MANAGEMENT;

DRUG COSTS; DRUG INDUSTRY; HEALTH CARE COSTS; HEALTH EXPENDITURES; RISK SHARING, FINANCIAL;

EID: 45749087693     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826070-00002     Document Type: Review

References (23)

1. Barham L, Bramley-Harker E. The MS risk-sharing scheme: eighteen months on. Pharma Pricing Reimbursement 2004 Jan; 9 (1): 8-9
2. Barham L. Multiple sclerosis risk-sharing: four years on. Pharma Pricing Reimbursement 2006 Apr; 11 (4): 100-1
3. Barham L. Velcade: the rise of risk-sharing in the UK. Pharma Pricing Reimbursement 2007 Sep; 12 (9): 272-3
4. Vecchione A. Hospital explores sharing risk with drugmakers. Drug Topics 2004 May 17 [online]. Available from URL: http://drugtopics.modernmedicine.com/ drugtopics/article/articleDetail.jsp?id=109857 [Accessed 2008 May 7]
5. United Kingdom Office of Fair Trading. The pharmaceutical price regulation scheme. London: United Kingdom Office of Fair Trading, 2007 Feb [online]. Available from URL: http://www.oft.gov.uk/shared_oft/reports/ comp_policy/oft885.pdf [Accessed 2008 May 7]
6. United States Centers for Medicare & Medicaid. National Health Care Expenditure Data: table 2. National health expenditures aggregate amounts and average annual percent change, by type of expenditure: selected calendar years 1960-2006 [online]. Available from URL: http://www.cms.hhs.gov/ NationalHealthExpendData/downloads/tables.pdf [Accessed 2008 Jan 28]
7. Dubois RW, Chawla AJ, Neslusan CA, et al. Explaining drug spending trends: does perception match reality? Health Aff 2000; 19 (2): 231-9
8. Berndt ER. Pharmaceuticals in US health care: determinants of quantity and price. J Econ Perspect 2002; 16 (4): 45-66
9. Scherer FM. Pricing, profits, and technological progress in the pharmaceutical industry. J Econ Perspectives 1993; 7 (3): 97-115
10. Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff 2001; 20 (5): 241-51
11. DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Managerial Decision Econ 2007; 28: 469-79
12. Grabowski HG, Vernon JM. A new look at the returns and risks to pharmaceutical R&D. Manage Science 1990; 36 (7): 804-21
13. Arrow KJ. Uncertainty and the welfare economics of medical care. Am Econ Rev 1963; 53 (5): 941-73
14. Grabowski HG, Vernon JM. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. J Law Econ 1992; 35: 331-50
15. Lichtenberg FR. Do (more and better) drugs keep people out of hospitals? Am Econ Rev 1996; 86 (2): 384-8
16. Long G, Cutler D, Berndt ER, et al. The impact of antihypertensive drugs on the number and risk of death, stroke and myocardial infarction in the United States [NBER working paper no. 12096]. NBER 2006 Mar [online]. Available from URL: http://www.nber.org/papers/w12096.pdf?new_window=1 [Accessed 2008 May 7]
17. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J Health Econ 2005; 24: 1-31
18. United States General Accounting Office. Prescription drugs: implications of drug labeling and off-label use GAO/THEHS-96-212 1996 Sep 12 [online]. Available from URL: http://www.gao.gov/archive/1996/he96212t.pdf. [Accessed 2008 May 7]
19. Anand G. Burden of proof: as costs rise, new medicines face pushback: insurers limit coverage to FDA-approved uses. $300 000 drug denied. Wall Street J 2007 Sep 18, A1
20. Appleby J. USA Today. Off-label drugs denied to patients in Medicare D [online]. Available from URL: http://www.usatoday.com/money/industries/health/ 2007-08-01-medicare-drugs_N.htm. [Accessed 2008 May 7]
21. Pollack A. Pricing pills by the results. New York Times 2007 Jul 14 [online]. Available from URL: http://www.nytimes.com/2007/07/14/business/ 14drugprice.html?ex=1342065600&en=e0184d170e89d16d&ei=5090&partner= rssuserland&emc=rss [Accessed 2008 May 7]
22. Barzel Y. Measurement cost and the organization of markets. J Law Econ 1982 Apr; 25 (1): 27-48
23. Lutz N. Warranties as signals under consumer moral hazard. RAND J Econ 1989 Summer; 20 (2): 239-255